VERV Quote, Financials, Valuation and Earnings

Intellia Therapeutics has a net margin of -94.11% compared to Verve Therapeutics's net margin of -687.61%. Verve Therapeutics's return on equity of -34.75% beat Intellia Therapeutics's return on equity of -56.9%.

Verve Therapeutics has a consensus price target of $15.11, signalling upside risk potential of 37.97%. On the other hand Intellia Therapeutics has an analysts' consensus of $37.11 which suggests that it could grow by 213.7%. Given that Intellia Therapeutics has higher upside potential than Verve Therapeutics, analysts believe Intellia Therapeutics is more attractive than Verve Therapeutics.

Verve Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intellia Therapeutics has a beta of 2.211, suggesting its more volatile than the S&P 500 by 121.143%.

Verve Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verve Therapeutics pays -- of its earnings as a dividend. Intellia Therapeutics pays out -- of its earnings as a dividend.

Verve Therapeutics quarterly revenues are $33M, which are larger than Intellia Therapeutics quarterly revenues of $16.6M. Verve Therapeutics's net income of -$31M is higher than Intellia Therapeutics's net income of -$114.3M. Notably, Verve Therapeutics's price-to-earnings ratio is -- while Intellia Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verve Therapeutics is 15.91x versus 26.18x for Intellia Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -94.11% compared to Verve Therapeutics's net margin of 26.7%. Verve Therapeutics's return on equity of -34.75% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Verve Therapeutics has a consensus price target of $15.11, signalling upside risk potential of 37.97%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $728.55 which suggests that it could grow by 32.46%. Given that Verve Therapeutics has higher upside potential than Regeneron Pharmaceuticals, analysts believe Verve Therapeutics is more attractive than Regeneron Pharmaceuticals.

Verve Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.325, suggesting its less volatile than the S&P 500 by 67.458%.

Verve Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.32% to investors and pays a quarterly dividend of $0.88 per share. Verve Therapeutics pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Verve Therapeutics quarterly revenues are $33M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Verve Therapeutics's net income of -$31M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Verve Therapeutics's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 14.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verve Therapeutics is 15.91x versus 4.46x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sage Therapeutics has a net margin of -94.11% compared to Verve Therapeutics's net margin of -442.4%. Verve Therapeutics's return on equity of -34.75% beat Sage Therapeutics's return on equity of -64.19%.

Verve Therapeutics has a consensus price target of $15.11, signalling upside risk potential of 37.97%. On the other hand Sage Therapeutics has an analysts' consensus of $8.73 which suggests that it could fall by -4.5%. Given that Verve Therapeutics has higher upside potential than Sage Therapeutics, analysts believe Verve Therapeutics is more attractive than Sage Therapeutics.

Verve Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.557%.

Verve Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verve Therapeutics pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

Verve Therapeutics quarterly revenues are $33M, which are larger than Sage Therapeutics quarterly revenues of $14.1M. Verve Therapeutics's net income of -$31M is higher than Sage Therapeutics's net income of -$62.2M. Notably, Verve Therapeutics's price-to-earnings ratio is -- while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verve Therapeutics is 15.91x versus 11.80x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -94.11% compared to Verve Therapeutics's net margin of -60.08%. Verve Therapeutics's return on equity of -34.75% beat Sarepta Therapeutics's return on equity of -20.94%.

Verve Therapeutics has a consensus price target of $15.11, signalling upside risk potential of 37.97%. On the other hand Sarepta Therapeutics has an analysts' consensus of $44.16 which suggests that it could grow by 101%. Given that Sarepta Therapeutics has higher upside potential than Verve Therapeutics, analysts believe Sarepta Therapeutics is more attractive than Verve Therapeutics.

Verve Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.448, suggesting its less volatile than the S&P 500 by 55.179%.

Verve Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verve Therapeutics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Verve Therapeutics quarterly revenues are $33M, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Verve Therapeutics's net income of -$31M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Verve Therapeutics's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verve Therapeutics is 15.91x versus 1.09x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.